Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Patients’ satisfaction in early breast cancer treatment: Change in treatment over time and impact of HER2-targeted therapy

Abstract : Although breast cancer remains a major cause of cancer death, its related death rate has dropped in the last years through early tumor detection and better available treatments. With the development of innovative techniques and new molecules as well as new routes of administration, local treatment and adjuvant therapy of early breast cancer have evolved, from mutilating, time-consuming and/or painful procedures to breast-conservative ones, sparing healthy tissues, reducing the total dose of treatment and the treatment time which in turn reduce the occurrence and severity of toxicity. In parallel with these improvements leading to an increase in survival rate, patients' health-related quality of life has become a major concern. This review aims at describing the evolution of early breast cancer treatment, and its impact on patients' quality of life, convenience, and satisfaction, including a special insight into emerging human epidermal growth factor receptor 2 (HER2)-targeted therapy.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02286307
Contributeur : Mélanie Karli <>
Soumis le : vendredi 13 septembre 2019 - 15:35:34
Dernière modification le : dimanche 15 septembre 2019 - 01:19:41

Identifiants

Citation

Jean-Philippe Spano, David Azria, Anthony Gonçalves. Patients’ satisfaction in early breast cancer treatment: Change in treatment over time and impact of HER2-targeted therapy. Critical Reviews in Oncology/Hematology, Elsevier, 2015, 94 (3), pp.270-278. ⟨10.1016/j.critrevonc.2015.01.007⟩. ⟨hal-02286307⟩

Partager

Métriques

Consultations de la notice

35